Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study

Autor: Anna Axelsson Raja, Peder E. Warming, Ture L. Nielsen, Louis L. Plesner, Mads Ersbøll, Morten Dalsgaard, Morten Schou, Casper Rydahl, Lisbet Brandi, Kasper Iversen

Publikováno v: BMC Nephrology, Vol 21, Iss 1, Pp 1-9 (2020)

Abstract Background Cardiovascular disease is the most common cause of death in patients with end-stage kidney disease on haemodialysis. The potential clinical consequence of systematic echocardiographic assessment is however not clear. In an unselec

Externí odkaz: https://doaj.org/article/48cb4f9aff124c54b899c8cbbc18f596

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Autor: Emil Wolsk, Mikkel Jürgens, Morten Schou, Mads Ersbøll, Philip Hasbak, Andreas Kjær, Bo Zerahn, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing, Jens Faber, Silvio E. Inzucchi, Caroline Michaela Kistorp, Finn Gustafsson

Publikováno v: Wolsk, E, Jürgens, M, Schou, M, Ersbøll, M, Hasbak, P, Kjær, A, Zerahn, B, Brandt, N H, Gæde, P H, Rossing, P, Faber, J, Inzucchi, S E, Kistorp, C M & Gustafsson, F 2022, ' Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk : The SIMPLE Trial ', Diabetes, vol. 71, no. 4, pp. 812-820 . https://doi.org/10.2337/db21-0721

Treatment with the sodium–glucose cotransporter 2 inhibitor (SGLT-2i) empagliflozin significantly reduces cardiovascular events in patients with type 2 diabetes (T2D); however, the mechanisms behind the reduction in cardiovascular (CV) events are u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0470bb1c03ac8c0f45c9d07d7f8d4f3
https://doi.org/10.2337/db21-0721

Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk:the SIMPLE randomized clinical trial

Autor: Finn Gustafsson, Andreas Kjaer, Mikkel Jürgens, Caroline Kistorp, Niels H Brandt-Jacobsen, Mads Ersbøll, Peter Gæde, Silvio E. Inzucchi, Philip Hasbak, Morten Schou, Jens Faber, Peter Rossing, Emil Wolsk, Bo Zerahn

Publikováno v: Ersbøll, M, Jürgens, M, Hasbak, P, Kjær, A, Wolsk, E, Zerahn, B, Brandt-Jacobsen, N H, Gæde, P, Rossing, P, Faber, J, Inzucchi, S E, Gustafsson, F, Schou, M & Kistorp, C 2022, ' Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk : the SIMPLE randomized clinical trial ', International Journal of Cardiovascular Imaging, vol. 38, pp. 579-587 . https://doi.org/10.1007/s10554-021-02443-5

To investigate the effects of 13 weeks treatment with empagliflozin in patients with high-risk type-2 diabetes mellitus on echocardiographic measures of left ventricular (LV) structure and function compared to placebo. A total of 91 patients were ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c55b34cd10b4b096b92cf6c3e47b21
https://portal.findresearcher.sdu.dk/da/publications/4eacac81-f529-42cb-8710-5f19bf255640

Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study

Autor: Peder Emil Warming, Casper Rydahl, Mads Ersbøll, Morten Dalsgaard, Kasper Iversen, Ture Lange Nielsen, Anna Axelsson Raja, Lisbet Brandi, Morten Schou, Louis Lind Plesner

Publikováno v: Axelsson Raja, A, Warming, P E, Nielsen, T L, Plesner, L L, Ersbøll, M, Dalsgaard, M, Schou, M, Rydahl, C, Brandi, L & Iversen, K 2020, ' Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis : An observational study ', BMC Nephrology, vol. 21, no. 1, 413 . https://doi.org/10.1186/s12882-020-02074-3
BMC Nephrology, Vol 21, Iss 1, Pp 1-9 (2020)
BMC Nephrology

Background Cardiovascular disease is the most common cause of death in patients with end-stage kidney disease on haemodialysis. The potential clinical consequence of systematic echocardiographic assessment is however not clear. In an unselected, cont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54546454afa2577378d5a454a5ae9832
https://doi.org/10.1186/s12882-020-02074-3

Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial

Autor: Steven McNulty, Gregory D. Lewis, Grace Lin, Mads Ersbøll, Marc J. Semigran, Adrian F. Hernandez, Justin M. Vader, Margaret M. Redfield, Eric J. Velazquez, Adam D. DeVore, Jae K. Oh, Fawaz Alenezi, Kevin J. Anstrom

Publikováno v: European Journal of Heart Failure. 19:893-900

BACKGROUND While abnormal left ventricular (LV) global longitudinal strain (GLS) has been described in patients with heart failure with preserved ejection fraction (HFpEF), its prevalence and clinical significance are poorly understood. METHODS AND R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e13a59162c512409b577d8ef26fd5a76
https://doi.org/10.1002/ejhf.754